Change in total lesion PSMA (TLP) during [177Lu]Lu-PSMA-617 radioligand therapy predicts overall survival in patients with mCRPC: monocentric evaluation of a prospective registry.

Purpose: This study investigates imaging response of [177Lu]Lu-PSMA-617 radioligand therapy (RLT) based on the whole-body parameter total lesion PSMA (TLP), derived by PSMA-PET/CT and reflecting the total tumor burden, in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled...

Descripción completa

Detalles Bibliográficos
Publicado en:European Journal of Nuclear Medicine & Molecular Imaging Vol. 51; no. 3; pp. 885 - 896
Autores principales: Burgard, Caroline, Hein, Connor, Blickle, Arne, Bartholomä, Mark, Maus, Stephan, Petto, Sven, Schaefer-Schuler, Andrea, Ezziddin, Samer, Rosar, Florian
Formato: Journal Article
Publicado: Springer Nature Feb2024
Acceso en línea:Ver este registro en EBSCOhost